Do analysts prefer RYM or ZIVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, RYM or ZIVO?

ZIVO Bioscience has lower revenue, but higher earnings than RYTHM. ZIVO Bioscience is trading at a lower price-to-earnings ratio than RYTHM, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RYTHM $17.28M 2.40 -$33.26M -$10.53 N/A ZIVO Bioscience $15.85K 1,090.32 -$7.78M -$1.40 N/A

Is RYM or ZIVO more profitable?

ZIVO Bioscience has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. ZIVO Bioscience's return on equity of 0.00% beat RYTHM's return on equity. Company Net Margins Return on Equity Return on Assets RYTHM -6.20% -12.57% -2.60% ZIVO Bioscience N/A N/A -2,240.92%

Do analysts rate DWTX or ZIVO?

Dogwood Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 689.47%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dogwood Therapeutics is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is DWTX or ZIVO more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -75.55% -40.28% ZIVO Bioscience N/A N/A -2,240.92%

Is AGFY or ZIVO more profitable?

ZIVO Bioscience has a net margin of 0.00% compared to Agrify's net margin of -424.11%. ZIVO Bioscience's return on equity of 0.00% beat Agrify's return on equity. Company Net Margins Return on Equity Return on Assets Agrify -424.11% -185.90% -72.67% ZIVO Bioscience N/A N/A -2,240.92%

Do analysts rate ZIVO or GRCE?

Grace Therapeutics has a consensus target price of $6.00, indicating a potential upside of 191.26%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Grace Therapeutics is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Grace Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ZIVO or GRCE more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Grace Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% Grace Therapeutics N/A -36.11% -34.39%

Do analysts recommend ZIVO or SCYX?

SCYNEXIS has a consensus target price of $33.00, suggesting a potential upside of 556.06%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts plainly believe SCYNEXIS is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is ZIVO or SCYX more profitable?

ZIVO Bioscience's return on equity of 0.00% beat SCYNEXIS's return on equity. Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% SCYNEXIS N/A -44.15% -32.61%

ZIVO Bioscience (ZIVO) Competitors

$4.10 0.00 (0.00%)

As of 10/5/2026 12:03 PM Eastern

Compare

ZIVO vs. RYM, DWTX, AGFY, GRCE, and SCYX

Should you buy ZIVO Bioscience stock or one of its competitors? ZIVO Bioscience's main competitors and comparable companies include RYTHM (RYM), Dogwood Therapeutics (DWTX), Agrify (AGFY), Grace Therapeutics (GRCE), and SCYNEXIS (SCYX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ZIVO Bioscience compare to RYTHM?

RYTHM (NASDAQ:RYM) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

In the previous week, RYTHM's average media sentiment score of 0.00 equaled ZIVO Bioscience'saverage media sentiment score.

Company	Overall Sentiment
RYTHM	Neutral
ZIVO Bioscience	Neutral

ZIVO Bioscience has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. ZIVO Bioscience's return on equity of 0.00% beat RYTHM's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
ZIVO Bioscience	N/A	N/A	-2,240.92%

RYTHM has a beta of 9.46, meaning that its share price is 846% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

6.0% of RYTHM shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 3.5% of RYTHM shares are owned by insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ZIVO Bioscience has lower revenue, but higher earnings than RYTHM. ZIVO Bioscience is trading at a lower price-to-earnings ratio than RYTHM, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$17.28M	2.40	-$33.26M	-$10.53	N/A
ZIVO Bioscience	$15.85K	1,090.32	-$7.78M	-$1.40	N/A

Summary

ZIVO Bioscience beats RYTHM on 8 of the 12 factors compared between the two stocks.

How does ZIVO Bioscience compare to Dogwood Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Dogwood Therapeutics' average media sentiment score of 0.00 equaled ZIVO Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Dogwood Therapeutics	Neutral
ZIVO Bioscience	Neutral

Dogwood Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 689.47%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dogwood Therapeutics is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 0.3% of Dogwood Therapeutics shares are held by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ZIVO Bioscience has higher revenue and earnings than Dogwood Therapeutics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A
ZIVO Bioscience	$15.85K	1,090.32	-$7.78M	-$1.40	N/A

Dogwood Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

ZIVO Bioscience's return on equity of 0.00% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-75.55%	-40.28%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Summary

Dogwood Therapeutics and ZIVO Bioscience tied by winning 6 of the 12 factors compared between the two stocks.

How does ZIVO Bioscience compare to Agrify?

Agrify (NASDAQ:AGFY) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Agrify has a beta of 9.96, meaning that its share price is 896% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

6.0% of Agrify shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 2.2% of Agrify shares are owned by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ZIVO Bioscience has a net margin of 0.00% compared to Agrify's net margin of -424.11%. ZIVO Bioscience's return on equity of 0.00% beat Agrify's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agrify	-424.11%	-185.90%	-72.67%
ZIVO Bioscience	N/A	N/A	-2,240.92%

In the previous week, Agrify's average media sentiment score of 0.00 equaled ZIVO Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Agrify	Neutral
ZIVO Bioscience	Neutral

ZIVO Bioscience has lower revenue, but higher earnings than Agrify. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Agrify, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agrify	$12.26M	3.20	-$41.75M	-$22.65	N/A
ZIVO Bioscience	$15.85K	1,090.32	-$7.78M	-$1.40	N/A

Summary

ZIVO Bioscience beats Agrify on 8 of the 11 factors compared between the two stocks.

How does ZIVO Bioscience compare to Grace Therapeutics?

ZIVO Bioscience (NASDAQ:ZIVO) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by company insiders. Comparatively, 10.8% of Grace Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ZIVO Bioscience has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

Grace Therapeutics has a consensus target price of $6.00, indicating a potential upside of 191.26%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Grace Therapeutics is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ZIVO Bioscience's return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Grace Therapeutics	N/A	-36.11%	-34.39%

In the previous week, Grace Therapeutics had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 1 mentions for Grace Therapeutics and 0 mentions for ZIVO Bioscience. Grace Therapeutics' average media sentiment score of 0.91 beat ZIVO Bioscience's score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Grace Therapeutics	Positive

ZIVO Bioscience has higher revenue and earnings than Grace Therapeutics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,090.32	-$7.78M	-$1.40	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A

Summary

ZIVO Bioscience and Grace Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does ZIVO Bioscience compare to SCYNEXIS?

ZIVO Bioscience (NASDAQ:ZIVO) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

ZIVO Bioscience has higher earnings, but lower revenue than SCYNEXIS. ZIVO Bioscience is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,090.32	-$7.78M	-$1.40	N/A
SCYNEXIS	$20.60M	2.43	-$8.61M	-$2.09	N/A

In the previous week, SCYNEXIS had 4 more articles in the media than ZIVO Bioscience. MarketBeat recorded 4 mentions for SCYNEXIS and 0 mentions for ZIVO Bioscience. SCYNEXIS's average media sentiment score of 0.53 beat ZIVO Bioscience's score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the news media.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
SCYNEXIS	Positive

ZIVO Bioscience's return on equity of 0.00% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
SCYNEXIS	N/A	-44.15%	-32.61%

SCYNEXIS has a consensus target price of $33.00, suggesting a potential upside of 556.06%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts plainly believe SCYNEXIS is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by company insiders. Comparatively, 4.1% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ZIVO Bioscience has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Summary

SCYNEXIS beats ZIVO Bioscience on 9 of the 15 factors compared between the two stocks.

Get ZIVO Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZIVO vs. The Competition

Export

Metric	ZIVO Bioscience	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$17.28M	$12.23B	$7.14B	$13.44B
Dividend Yield	N/A	2.65%	2.54%	17.38%
P/E Ratio	-0.84	799.75	274.31	26.29
Price / Sales	1,090.32	842.30	597.55	86.17
Price / Cash	N/A	15.08	27.22	34.70
Price / Book	-5.06	10.66	11.13	6.38
Net Income	-$7.78M	$2.84B	$3.50B	$381.07M
7 Day Performance	N/A	-2.13%	-1.88%	-0.28%
1 Month Performance	N/A	-6.73%	-6.63%	-4.51%
1 Year Performance	-65.11%	-4.97%	6.10%	1.57%

ZIVO Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZIVO ZIVO Bioscience	N/A	$4.10 flat	N/A	-65.1%	$17.28M	$15.85K	N/A	10
RYM RYTHM	0.1395 of 5 stars	$22.03 -0.5%	N/A	-55.7%	$48.03M	$17.28M	N/A	141	Gap Up
DWTX Dogwood Therapeutics	3.0111 of 5 stars	$1.38 -3.8%	$12.00 +772.7%	-76.3%	$46.74M	N/A	N/A	8	News Coverage Gap Up
AGFY Agrify	N/A	$23.01 -2.0%	N/A	-54.3%	$46.09M	$12.26M	N/A	140
GRCE Grace Therapeutics	2.003 of 5 stars	$2.13 -1.4%	$6.00 +181.7%	-32.0%	$44.82M	N/A	N/A	5	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZIVO) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ZIVO Bioscience (ZIVO) Competitors

ZIVO vs. RYM, DWTX, AGFY, GRCE, and SCYX

How does ZIVO Bioscience compare to RYTHM?

Summary

How does ZIVO Bioscience compare to Dogwood Therapeutics?

Summary

How does ZIVO Bioscience compare to Agrify?

Summary

How does ZIVO Bioscience compare to Grace Therapeutics?

Summary

How does ZIVO Bioscience compare to SCYNEXIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO vs. The Competition

ZIVO Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ZIVO Bioscience (ZIVO) Competitors

ZIVO vs. RYM, DWTX, AGFY, GRCE, and SCYX

How does ZIVO Bioscience compare to RYTHM?

Does the media prefer RYM or ZIVO?

Is RYM or ZIVO more profitable?

Which has more risk & volatility, RYM or ZIVO?

Do analysts prefer RYM or ZIVO?

Do institutionals and insiders have more ownership in RYM or ZIVO?

Which has preferable valuation and earnings, RYM or ZIVO?

Summary

How does ZIVO Bioscience compare to Dogwood Therapeutics?

Does the media prefer DWTX or ZIVO?

Do analysts rate DWTX or ZIVO?

Do insiders and institutionals have more ownership in DWTX or ZIVO?

Which has stronger earnings & valuation, DWTX or ZIVO?

Which has more risk and volatility, DWTX or ZIVO?

Is DWTX or ZIVO more profitable?

Summary

How does ZIVO Bioscience compare to Agrify?

Which has more risk & volatility, AGFY or ZIVO?

Do insiders and institutionals have more ownership in AGFY or ZIVO?

Is AGFY or ZIVO more profitable?

Does the media favor AGFY or ZIVO?

Which has stronger earnings and valuation, AGFY or ZIVO?

Summary

How does ZIVO Bioscience compare to Grace Therapeutics?

Do insiders and institutionals believe in ZIVO or GRCE?

Which has more volatility & risk, ZIVO or GRCE?

Do analysts rate ZIVO or GRCE?

Is ZIVO or GRCE more profitable?

Does the media prefer ZIVO or GRCE?

Which has preferable earnings and valuation, ZIVO or GRCE?

Summary

How does ZIVO Bioscience compare to SCYNEXIS?

Which has preferable earnings & valuation, ZIVO or SCYX?

Does the media favor ZIVO or SCYX?

Is ZIVO or SCYX more profitable?

Do analysts recommend ZIVO or SCYX?

Do institutionals & insiders hold more shares of ZIVO or SCYX?

Which has more risk and volatility, ZIVO or SCYX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO vs. The Competition

ZIVO Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools